Swiss drug manufacturing supplier Lonza used its Oct. 14 Capital Markets Day to raise its mid-term targets, even as it said its 2026 third-quarter performance was in line and warned that currency moves could trim 2-3% off this year's reported sales growth.
The company now targets 10-13% organic constant-exchange-rate sales growth and a core EBITDA margin in the high thirties over time, according to Reuters. For 2026, it reiterated an outlook of 11-12% constant-currency sales growth and a 33-34% core EBITDA margin, while noting that foreign-exchange swings could reduce reported growth by 2-3%.
What's behind the new targets
Lonza is a contract development and manufacturing organization (CDMO), meaning it produces drugs and therapies for other pharmaceutical companies. Its growth depends on winning and retaining contracts from big pharma and biotech firms, which outsource manufacturing to specialists like Lonza to save time and money.
The raised targets suggest Lonza sees sustained demand for its services, particularly in areas like biologics and cell and gene therapy, where manufacturing is complex and capacity is scarce. The company also pointed to mid-single-digit growth and margin expansion in its Capsules & Health Ingredients unit, indicating the plan isn't riding on one business line.
But the bigger signal was capital discipline. Lonza added a mid-term goal for return on invested capital (ROIC) to reach two to three times its weighted average cost of capital (WACC). It kept capital spending around a mid- to high-teens share of sales and said it wants better free-cash-flow conversion.
Why the return target matters
For investors, the new ROIC goal changes how they should judge Lonza's growth plan. A 10-13% constant-currency growth target sounds good, but markets care most about whether that growth creates value after the bill for funding it. By aiming for returns on invested capital at two to three times its cost of capital, Lonza is saying new factories, capacity, and acquisitions should pay back comfortably more than they cost to finance.
That widens the "economic profit" spread investors look for, and it can support a higher valuation if the company proves it's real. The catch is execution: with capital spending still slated to run at a mid- to high-teens percentage of sales, the key proof point becomes free cash flow, because strong margins don't automatically translate into cash when a business is reinvesting heavily.
So the debate around Lonza is likely to shift from whether it can hit its growth rate to whether it can sustain high-thirties core EBITDA margins while also improving cash conversion and returns over time.
What it means for investors
For everyday investors, Lonza's announcement is a reminder that growth alone isn't enough. A company can grow revenue and even improve margins, but if it has to pour ever more money into capital expenditures to achieve that growth, shareholders may see little benefit. The new ROIC target signals that Lonza's management is aware of this and is trying to reassure investors that growth will be profitable and cash-generative.
Currency is another factor to watch. Lonza reports in Swiss francs, and a strong franc can reduce the value of sales made in other currencies. The 2-3% hit to reported growth this year is a reminder that exchange rates can mask underlying performance. Investors should focus on constant-currency figures when comparing results across periods.
Lonza's move comes as other companies in the sector are also emphasizing capital efficiency. For example, Rio Tinto recently touted a $5 billion capital release, highlighting a broader trend among large industrials to return cash to shareholders. While Lonza isn't promising buybacks, its focus on cash conversion and ROIC is in the same spirit.
Investors will now watch Lonza's quarterly results for evidence that the new targets are achievable. The company's ability to maintain high-thirties margins while investing heavily will be a key test. If it succeeds, the stock could re-rate higher; if it falls short, the market may question whether the growth is worth the capital it consumes.
For those looking at the broader market, Lonza's update comes amid a mixed global backdrop. The IMF recently lifted its global growth forecast, but concerns about inflation and central bank policy persist. Singapore's growth cooled while its central bank held policy, and Westpac's leading index signals slow Australian growth ahead. These mixed signals suggest that companies like Lonza, which have strong structural tailwinds, may be better positioned than cyclical names.
In the end, Lonza's raised targets are a positive signal, but the proof will be in the execution. Investors should keep an eye on free cash flow and ROIC in the coming quarters to see if the company can deliver on its promises.
